|Application ||WB, IF|
|Calculated MW||11175 Da|
|Other Names||Apolipoprotein A-II, Apo-AII, ApoA-II, Apolipoprotein A2, Proapolipoprotein A-II, ProapoA-II, Truncated apolipoprotein A-II, Apolipoprotein A-II(1-76), APOA2|
|Target/Specificity||A synthetic peptide corresponding to residues in human Apolipoprotein A-II (ApoA-II) was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Apolipoprotein A-II (ApoA-II) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||May stabilize HDL (high density lipoprotein) structure by its association with lipids, and affect the HDL metabolism.|
|Tissue Location||Plasma; synthesized in the liver and intestine|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Apolipoprotein A II is the second most abundant protein of the high density lipoprotein particles, accounting for 20% of protein mass of HDL. The concentration of ApoA-I and ApoA-II is inversely correlated with the frequency of heart disease in human (1). In studies with mice and humans, ApoA-II levels have been associated with increased susceptibility to atherosclerosis, increased free fatty acid levels, increased body fat, and increased insulin resistance (2). ApoA-II consists of three potential amphipathic helices of 17 residues each, which contribute to the lipid-binding properties of this apolipoprotein (3). Currently, the best characterized activity of apoA-II is its potent antagonism of the anti-atherogenic and anti-inflammatory activities of ApoA-I, probably due to its competition with the latter for lipid acyl side chains of HDL (1).
1. Kumar et al. Biochemistry. 41 (39):11681-11691, 2002 2. Castellani and Lusis. Arterioscler. Thromb. Vasc. Biol. 21:1870-1872, 2001 3. Benetollo et al. Eur. J. Biochem. 242 :657-664, 1996
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.